INTRODUCTION
Colon cancer is the third most common malignancy worldwide, and it stands as the second most common cause of cancer mortality in western countries (1) . Most of these deaths are due to liver metastatic disease, and the prognosis and the overall survival are mainly determined by the progression of the primary carcinoma. An increasingly accepted concept is that colon cancer progression is accompanied by a cellular pathway often referred to as the epithelial-to-mesenchymal transition (EMT), an important preliminary step in metastasis (2) that allows cells to become motile.
During EMT carcinoma cells become more invasive and aggressive, with loss of epithelial characteristics that cause dissociation from surrounding cells and acquisition of mesenchymal-like properties that allow them to migrate away from the initial neoplastic focus. Thus, the major molecular hallmarks of EMT include down-regulation of junctional protein E-cadherin responsible for the loss of cell-cell adhesion, and expression of mesenchymal proteins like vimentin and Ncadherin. Furthermore, cells undergoing EMT express matrix metalloprotease enzymes, the primary mechanism accounting for tumour invasion that allows penetration within the stroma surrounding the original tissue.
Functional changes of EMT take place through complex molecular events involving systems and signalling proteins: central in signalling pathways that lead to E-cadherin repression is the activation of the zinc finger factor SNAI1, a strong repressor of E-cadherin transcription, which is overexpressed in colon cancer cells (3) .
Another environmental regulator promoting tumour aggressiveness is intratumoral hypoxia, whose importance in development of colon cancer has been well demonstrated by clinical studies in which hypoxia predicts for poor prognosis. Hypoxia may also influence tumour-associated stromal cells, in a way that may contribute to patient prognosis.
As recently confirmed in human hepatocellular cancer cells hypoxia is able to induce EMT and increased invasiveness in human cancer cells (4, 5) .
A major mechanism which is likely to link hypoxia to cancer progression is represented by the expression of proteins that favour tumour invasiveness through adaptative mechanisms involving specific hypoxia-inducible transcription factors (HIFs) and resulting in the induction of critical phenotypic and functional cellular changes. Along these lines, HIF-1 is a transcription factor overexpressed in many solid tumours, whose stabilization and activation correlates with tumour metastasis and poor prognosis. HIF-1 might contribute to tumour progression through the promotion of angiogenesis, the activation/induction of proteolitic enzymes or the activation of genes involved in tumour cell invasiveness. HIF-1 can also induce EMT, through the activation of EMT regulators, including SNAI1, although the expression of EMT-related transcription factors Cells were seeded in 75 cm 2 plates and properly treated. Total extracts, nuclear extracts and membrane-associated fractions were obtained as previously detailed (23). Protein contents were measured using a commercially available assay (Protein Assay Kit 2, Biorad) with bovine serum albumin as a standard. Extracts were then subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis on 12, 10 or 7.5% acrylamide gels. The blots were incubated with desired primary antibody and then incubated with peroxidase-conjugated anti-mouse or anti-rabbit antibodies in
Tris-buffered saline-Tween containing 2% (wt/vol) non-fat dry milk, and developed with the enhanced chemiluminescence reagents. Band intensities were quantified by densitometry and the expression of proteins was reported as a proportion of -actin protein expression to monitor any discrepancies in gel loading (VersaDoc Imaging System 3000, Biorad).
Fluorescence microscopy
Cells were seeded on 6-well culture plates, allowed to adhere for 24 h and then treated. After treatment, the cells were fixed and permeabilized with methanol/acetone (1:1). Cells were then incubated with antibodies for E-cadherin, αSMA, β-catenin or vimentin and the immunopositivity was revealed by means of appropriate Cy3-conjugated secondary antibody. Then cells were stained with Hoechst to detect nuclei. After washings with PBS, the slides were mounted with H 2 O/glycerol
(1:1) and viewed under a fluorescence microscope equipped with a UV light filter (Dialux 20, Leitz).
Invasion assay
Cells were seeded on 6-well culture plates, and properly treated. After treatment, cell invasiveness was evaluated with Boyden chambers equipped with 8 μm porosity polyvinylpyrrolidone-free polycarbonate filters coated with 50 μg/ml of Matrigel solution. After a 24 h incubation, the filters were fixed in ice-cold methanol and stained with crystal violet solution. The migrating cells were quantified in ten randomly selected fields at × 40 magnification in each filter, and the average value (mean ± SD) was defined on three independent filters.
Statistical analysis
Differences between the means were analyzed for significance using the one-way ANOVA test with Bonferroni post hoc multiple comparisons, used to assess the differences between independent groups. All values are expressed as means ± SD, and differences were considered significant at p<0.05.
RESULTS

Effect of celecoxib and EGF on HT-29 cell proliferation and on EGFR downstream signalling pathways.
In a first series of experiments we investigated whether celecoxib was able to interfere with EGFdependent intracellular signalling pathway. HT-29 cells were cultured for 1h with EGF (100 ng/ml) and celecoxib, alone or in combination, then rinsed in SFIF and cultured for additional 24, 48, and 72 h in serum-starved medium. Celecoxib was administered at a 50 μM concentration, since we reported previously that this concentration caused a strong (40-60%) reduction of HT-29 cell proliferation, also due to induction of apoptosis (23). As expected (figure 1A), EGF led to increased proliferation (significant at 24 and 72 h) whereas celecoxib treatment resulted in a very significant inhibition of basal (i.e., unstimulated) proliferation at any experimental time point, the most effective inhibition being detected at 48 and 72 h (approx. 60% inhibition vs control values).
Celecoxib, although to a lesser extent, also resulted in the inhibition of EGF-stimulated cell growth, with the strongest antiproliferative effect detected at 72 h incubation (approx. 50% inhibition vs
EGF-stimulated proliferation of HT-29 cells).
Since EGFR is over-expressed in a variety of malignancies including colon carcinoma (24) as well as in HT-29 cells we next evaluated whether celecoxib may affect either EGFR levels or levels of its phosphorylated form (figure 1B). Celecoxib treatment, irrespective of EGF exposure, resulted in a decrease of EGFR and pEGFR levels after 24 h. ERK activation represents an early step in growth factor-induced cell proliferation and additional experiments outlined the fact that changes in cell proliferation were correlated with changes in ERK phosphorylation ( figure 1C ). Pre-treatment with celecoxib resulted in a significant inhibition of pERK levels in control as well as in EGF-stimulated cells. A very similar scenario was also observed for changes in COX-2 levels, as well as for changes in pAkt and PI3K ( figure 1C,D) . We next analyzed PTEN activation, since PTEN is known to act as a negative regulator of PI3K and MAPK. As expected, PTEN expression was increased (2-fold) by celecoxib, whereas exposure to EGF resulted in a strong reduction of PTEN (approx. 50 %) and was not modified by concomitant treatment with celecoxib. antiproliferative effect at 50 μM on HT-29 cells, in particular on EGF-stimulated ones, whereas the reported inhibitory action of 10 μM celecoxib was definitively less effective ( figure 2A ).
HT-29 cells were then evaluated for changes in protein levels of COX-2, pERK and pAkt as well as for HIF-1α levels ( figure 2B ). Exposure to hypoxia resulted in a marked increased expression of HIF-1α, a scenario that was not significantly affected by EGF. Moreover, hypoxia led also to increased phosphorylation of ERK to levels comparable with those elicited by EGF; in particular, under hypoxic conditions EGF treatment induced a further enhancement of pERK levels.
Treatment with celecoxib resulted in a very significant (approx. 50%) reduction of pERK and HIF-1α levels in all experimental conditions, suggesting that the drug may affect signalling and transcription factors induced by hypoxia and then likely, responses of target cells. It should be noted that COX-2 expression was unmodified by either hypoxia or EGF but strongly decreased by celecoxib treatment under normoxic conditions. Unexpectedly, celecoxib-induced decrease in COX-2 levels was partially prevented when cells were cultured under hypoxia. By contrast, celecoxib was uneffective on changes of pAkt levels induced by either hypoxia and/or EGF.
Celecoxib affects early changes in EMT markers induced by hypoxia in HT-29 cells
On the basis of mentioned results, we inferred that in HT-29 cells celecoxib might inhibit hypoxiainduced EMT, a process that requires approximatively 72 h to occur (4) . In order to test such an hypothesis we analyzed critical parameters of hypoxia-induced EMT at an early time point (i.e., 24 h). We found that celecoxib was able to fully and significantly counteract early hypoxia-dependent decrease in E-cadherin levels and positive immune-staining, which indeed resulted both upregulated by celecoxib as compared to control values (figure 3A,B).
Whether mesenchymal markers such as vimentin and α-SMA are concerned, celecoxib treatment was found to significantly decrease hypoxia-induced up-regulation of vimentin (figure 4A,B).
However, when the action of celecoxib was evaluated in the presence of EGF alone or EGF and hypoxia, celecoxib treatment resulted in a significant reduction of vimentin levels only, but not of α-SMA, in these experimental conditions (figure 5A,B).
Celecoxib and EGF affect β-catenin intracellular localization under normoxic and hypoxic conditions in HT-29 cells
Since E-cadherin changes and Wnt/β-catenin pathway are known to be strictly connected in EMT induction we next examined whether celecoxib can affect β-catenin intracellular localization.
Treatment of HT-29 cells with celecoxib exposed to either hypoxic conditions alone, EGF (normoxic conditions) or to both EGF and hypoxia resulted in a clear and significant decrease in the nuclear fraction of β-catenin and in a parallel increase of β-catenin bound to the membrane fraction, suggesting that celecoxib may indeed reverse EMT induction (figure 6 A,B).
Celecoxib inhibits invasiveness of HT-29 cells
In order to further investigate the action of celecoxib on EMT-related parameters, we next examined whether the drug was also able to affect invasiveness of HT-29 cancer cells. Results are straightforward in indicating that celecoxib is highly efficient in abolishing either basal invasiveness as well as the one induced by hypoxia alone, EGF alone or by hypoxia plus EGF (figure 7).
Effect of celecoxib on viability, expression of E-cadherin, pERK and pEGFR in SW-480 cells under normoxic and hypoxic conditions
In the experiments depicted in figure 8 , When SW-480 cells were treated or not with celecoxib (50 μM) and exposed to either normoxic and hypoxic conditions we found results that were somewhat different from those observed for HT-29 cells. In particular, E-cadherin levels that were reduced under hypoxic conditions also in this cell line, were not reverted by celecoxib. On the other hand, pERK levels increased slightly under hypoxia, irrespective on the treatment with celecoxib ( figure 8B ).
Celecoxib inhibits hypoxia-induced invasiveness of both HT-29 and SW-480 cells
Since previous results were consistent with a significant effect exerted by celecoxib on critical parameters of EMT, we next performed in both HT-29 and SW-480 cells a comparative analysis of the drug action on hypoxia-induced invasiveness, chosen as a model condition for its "in vivo" putative relevance. Results are straightforward in indicating that in HT-29 cells both 10 and 50 μM celecoxib concentrations were highly effective (figure 9A) in inhibiting either basal as well as hypoxia-induced invasiveness. On the other hand, celecoxib displayed no or modest inhibitory effect on basal and hypoxia-induced invasiveness of SW-480 cells when used at either 10 μM or 50 μM concentration, respectively (figure 9B).
DISCUSSION
Celecoxib is currently used as a chemopreventive and therapeutic drug (25,26) and it has also been reported to display anticancer effects both in vivo (27) and in vitro in experimental models of colon cancer (23,28). However, no studies have addressed whether celecoxib may affect EMT, which is known to be relevant for cancer progression and metastasis formation. EMT is known to be regulated by signals coming from tumour microenvironment, including hypoxic conditions and several growth factors, cytokines and ECM proteins. In addition, tumours themselves can also release growth factors and proteases that are able to modify tumour microenvironment favouring cell motility and invasiveness.
The main message conveyed by the present study is that celecoxib can efficiently inhibit EMT promoted by EGF and hypoxia in colorectal cancer cells which is likely to be, at least in part, dependent on its classic major molecular mechanism leading to COX-2 inhibition. As far as EGFinduced EMT is concerned, celecoxib seems to act by inhibiting EGFR but literature on this matter is controversial. Indeed, literature data suggest the existence of a relationship between COX-2 and EGFR, since COX-2 has been identified as a putative EGF target gene in intestinal epithelial cells, with robust enhancement of prostaglandin production following EGFR activation (29). Several studies emphasize that colon carcinomas bearing increased COX-2-dependent production of prostaglandins are characterized by a very poor prognosis (30,31); moreover, COX-2-derived PGE2
has been reported to transactivate EGFR (11) which overexpression is also known to be associated with poor survival in patients with colorectal cancer. In agreement with these reports, we found that, celecoxib not only decreased EGFR activation/phosphorylation, but also reduced its expression levels, suggesting that the ability of celecoxib to inhibit EGFR downstream signalling pathways may represent a rather complex event. If this hypothesis applies, celecoxib may act similarly to other anticancer agents that have been proposed to exert their antiproliferative effects by promoting degradation or internalization of EGFR (32,33). Since this effect was also reported in COX-2 deficient SW-480 cells, celecoxib effects on EGFR may rely on COX-2 independent, but still unclear, mechanisms of action (22) .
EGF signalling is known to affect critical events, including cell differentiation, adhesion, motility and EMT induction, pointing to its unambiguous roles in tumour progression (34, 35) . Intratumoral hypoxia is another environmental condition able to induce EMT and increased invasiveness in human cancer cells (4) . Hypoxia may also affect tumour-associated stromal cells, and its relevance in the development of colon cancer has been outlined by studies in which hypoxia predicts for poor prognosis (5).
However, a direct mechanistic link between hypoxia, EMT and celecoxib action in colon cancer cells has never been described. To our knowledge, data in this study provide the first evidence on the putative role of celecoxib as negative regulator of hypoxia-induced EMT, with a mechanism that, based on results obtained for SW-480 cells, seems to mostly depend on COX-2inhibition. This statement is also suggested by results related to cell viability which indicate that the consistent inhibitory action of 50 µM concentration on HT-29 cells may be partly due to toxic effects, whereas the action of 10 µM concentration, which is less effective on viability, is likely to depend mainly on the inhibitory effect exerted by celecoxib on COX-2. On the other hand, in SW-480 COX-2-negative cells the inhibitory effect of both the concentrations of celecoxib on viability is not remarkable, confirming COX-2 inhibition as the main mechanism of action for this drug.
In this connection, it is well known that hypoxia is likely to contribute to cancer progression through adaptative mechanisms involving recruitment/stabilization of hypoxia-inducible transcription factors (HIFs). HIF-1 is overexpressed in many solid tumours and has been proposed to up-regulate genes involved in cell invasiveness and angiogenesis, with an overall scenario in which HIF-1 expression correlates with an increased risk to develop metastasis and a poor prognosis.
Although it is well known that under hypoxic conditions HIF-1α accumulation occurs because of the shutdown of the proteasomal degradation system in the absence of oxygen, it has also been reported that HIF-1α levels may be enhanced in tumor cells as a consequence of the action of several growth factors, including EGF. Indeed, under normoxic conditions, it has been shown that EGFR signalling activates the PI3K/Akt pathway, subsequently increasing HIF-1α levels (38, 39) .
Although PI3K has many potential downstream targets, we focused our attention on Akt because of several reports outlining the importance of this kinase, which is frequently constitutively active in cancer cells, for its functional role in aggressive, therapy-resistant malignancies (40) . Although several drugs are currently investigated for their ability to inhibit Akt signalling, in our hands celecoxib was unlikely to inhibit HIF-1α accumulation by exerting a negative effect on Akt activity. Furthermore, a "cadherin switch" has been described, whereby E-cadherin loss is accompanied by gain of N-cadherin (44) or vimentin and indeed it has been reported that vimentin expression is, in colon and other cancers, correlated closely with increased invasiveness and poor prognosis (45) . In the present study we provide evidence that celecoxib can induce a decrease in vimentin overexpression in HT-29 cells undergoing EMT following exposure to EGF and/or hypoxia.
In addition, endocytosis of E-cadherin is known to result in a mobilization of β-catenin that can then act on the Wnt pathway, resulting in further E-cadherin repression (9) . It has been reported that in tumour cells β-catenin is aberrantly activated and acts as a tumour-promoting factor, and HIF-1α
has been proposed to inactivate β-catenin by sequestering it under hypoxia (46) . Furthermore, many cancer cells express both HIF-1α and HIF-2α in response to hypoxia and it has been recently proposed that HIF-1α/HIF-2α balance may contribute to cell growth regulation when hypoxia and Wnt stimulation coexist (47) . We found that celecoxib reduced β-catenin nuclear accumulation and increased membrane-bound β-catenin, independently on hypoxic conditions. These results suggest that in addition to its role in COX-2 inactivation, celecoxib may contribute to inhibit cancer cell growth by modulating β-catenin signalling.
Furthermore, hypoxia has been described to induce migration and invasiveness in different cell lines and EGF (100 ng/ml), alone or in combination.
A: Viable cell number was then assessed by the trypan blue exclusion test after 24, 48 and 72 h.
Results are expressed as percentage versus control (100%) and values represent mean ± SD for three independent experiments, each performed in triplicate. * p<0.05, ** p<0.001 vs control.
B-D:
Whole cell lysates were analyzed by Western blotting with specific antibodies for COX-2, pERK, pEGFR, EGFR, PTEN, PI3K and pAkt and then with HRP-conjugated secondary antibody.
The blots were normalized with anti--actin antibody and quantified as arbitrary values relative to control by densitometry (SD < 10%). The data are representative of three independent experiments. HT-29 cells were incubated for 24h under normoxic and hypoxic conditions in the absence (control) or in the presence of celecoxib (50 μM) and EGF (100 ng/ml), alone or in combination. HT-29 cells were incubated for 24 h under normoxic or hypoxic conditions in the absence (control) or in the presence of celecoxib (50 μM) and EGF (100 ng/ml), alone or in combination.
A: Nuclear and membrane-associated fractions were routinely stained using Ponceau Red dye and analyzed by Western blotting with specific antibody for -catenin and then with HRP-conjugated secondary antibody. The blots were quantified as arbitrary values relative to control by densitometry (SD < 10%) and are representative of three independent experiments.
B:
The cells were fixed and exposed to primary antibody for -catenin followed by anti-mouse HT-29 cells were incubated for 24 h under normoxic and hypoxic conditions in the absence (control) or in the presence of celecoxib (50 μM) and EGF (100 ng/ml), alone or in combination.
Matrigel invasion was evaluated with a Boyden chamber assay; each filter was examined with a Zeiss microscope and the number of cells that penetrated through the matrigel was counted. Data are expressed as number of cells per high-power field and represent the mean of three independent experiments, each performed in triplicate (bars, SD). *p<0.001 significant difference between treated groups and the control. 
